logo-loader
viewAcelRx Pharmaceuticals

Small-Cap Snapshot: AcelRX Pharmaceuticals shares sink after public offering announcement

The biotech is offering more than 7 million shares, expecting to raise as much as US$20mln

1531406639_Doctor.jpg
Shares of its common stock have been priced at US$2.75 per share

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is a top decliner after announcing pricing of a public offering of common stock. The biotech is offering more than 7 million shares at a price of US$2.75 per share. The offering is expected to raise US$20mln to be used for general corporate purposes, including the funding of early commercialization efforts. The specialty pharma company develops under-the-tongue therapies for acute pain. Shares of the California-based company were down nearly 13% to US$2.97 in Thursday morning trading.

Zogenix Inc (NASDAQ:ZGNX) shares jumped following positive results from its late-stage trial of its epilepsy drug. The Phase 3 trial showed that its drug ZX008 was able to reduce the frequency of convulsive seizures. The drug is designed to treat children and young adults with Dravet syndrome. Shares of the California-based biotech were up more than 15% to US$53.42.

READ: Zogenix shares pop on impressive Phase 3 results for epilepsy drug

Engility Holdings Inc (NYSE:EGL) shares are up after reports that the government contractor is exploring a sale. The US defense contractor is said to have attracted companies like CACI International Inc and Science Applications International Corp, according to a Reuters report. The company provides engineering and logistics services to US military and civilian agencies. Shares of the company jumped more than 13% to US$35.79.

The Cato Corporation (NYSE:CATO) is another top decliner following disappointing sales in June. The apparel company reported below-expectation same-store sales. Sales decreased by 2% to US$72.9mln compared with sales of US$74.7mln last June. The company operates 1,350 stores in 33 states, 24 fewer stores than last year. Shares of the North Carolina-based company were down more than 13% to US$21.56.

The Russell 2000 Small-Cap Index saw minimal gains in Thursday morning trading.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

Quick facts: AcelRx Pharmaceuticals

Price: 2.26 USD

NASDAQ:ACRX
Market: NASDAQ
Market Cap: $179.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Things coming together nicely in Greenland, says Bluejay Mining's CEO

Rod McIllree, Bluejay Mining PLC’s (LON:JAY) chief executive, tells Proactive that all three of its projects in Greenland are shaping up nicely with plenty of interest from mining giants. Dundas is the flagship and here a bulk sample of mineral sands has been shipped to a Rio Tinto facility...

1 day, 7 hours ago

2 min read